154 related articles for article (PubMed ID: 26833957)
1. Design and analysis of clinical trials in the presence of delayed treatment effect.
Sit T; Liu M; Shnaidman M; Ying Z
Stat Med; 2016 May; 35(11):1774-9. PubMed ID: 26833957
[TBL] [Abstract][Full Text] [Related]
2. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
3. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
[TBL] [Abstract][Full Text] [Related]
4. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
5. Power and sample size calculation for log-rank test with a time lag in treatment effect.
Zhang D; Quan H
Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
[TBL] [Abstract][Full Text] [Related]
6. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
Wu J
J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
[TBL] [Abstract][Full Text] [Related]
7. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
9. A sample size formula for the supremum log-rank statistic.
Eng KH; Kosorok MR
Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
[TBL] [Abstract][Full Text] [Related]
10. Analysis of time-to-event data under a two-stage survival adaptive design in clinical trials.
Lu Q; Tse SK; Chow SC
J Biopharm Stat; 2010 Jul; 20(4):705-19. PubMed ID: 20496201
[TBL] [Abstract][Full Text] [Related]
11. Sample size calculation for the one-sample log-rank test.
Schmidt R; Kwiecien R; Faldum A; Berthold F; Hero B; Ligges S
Stat Med; 2015 Mar; 34(6):1031-40. PubMed ID: 25500942
[TBL] [Abstract][Full Text] [Related]
12. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
13. Adaptive designs for the one-sample log-rank test.
Schmidt R; Faldum A; Kwiecien R
Biometrics; 2018 Jun; 74(2):529-537. PubMed ID: 28940387
[TBL] [Abstract][Full Text] [Related]
14. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
15. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
Shan G
J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
[TBL] [Abstract][Full Text] [Related]
16. Sample size computation for two-sample noninferiority log-rank test.
Jung SH; Kang SJ; McCall LM; Blumenstein B
J Biopharm Stat; 2005; 15(6):969-79. PubMed ID: 16279355
[TBL] [Abstract][Full Text] [Related]
17. Blinded assessment of treatment effects for survival endpoint in an ongoing trial.
Xie J; Quan H; Zhang J
Pharm Stat; 2012; 11(3):204-13. PubMed ID: 22337644
[TBL] [Abstract][Full Text] [Related]
18. Sample size calculation for the one-sample log-rank test.
Wu J
Pharm Stat; 2015; 14(1):26-33. PubMed ID: 25339496
[TBL] [Abstract][Full Text] [Related]
19. Combining stratified and unstratified log-rank tests in paired survival data.
Oakes D; Feng C
Stat Med; 2010 Jul; 29(16):1735-45. PubMed ID: 20572124
[TBL] [Abstract][Full Text] [Related]
20. Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution.
Lu Q; Tse SK; Chow SC; Lin M
J Biopharm Stat; 2012; 22(4):773-84. PubMed ID: 22651114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
